$ABBNY

ABB Ltd Q2 Profit, Orders Climb; Sees Growth In Q3, Lifts FY26 Revenue View

ABB Ltd reported Q2 net income attributable to $1.23B, up 7% from $1.15B, and EPS of $0.68, up 8%. Revenues rose 14% to $9.475B and comparable revenues grew 12%. Orders increased 30% to $12.042B. ABB expects low- to mid-teens comparable revenue growth in Q3 and raised its FY2026 revenue outlook.

Original reporting
Published Jul 16, 2026, 6:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ABBNY
Bullish
medium confidence
Mentioned
$ABBNY
Relevance
8/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$ABBNYBullishMed
01

Why it matters

The key trade driver is the combination of upside Q2 fundamentals and an upgraded FY26 revenue outlook, alongside a positive book-to-bill expectation and improving operational EBITA margin trajectory.

02

Market read

Fresh Q2 profit, orders, and margin metrics plus raised Q3 and FY26 comparable revenue expectations create a near-term catalyst for positioning.

03

What to watch

The article mentions excluding a real estate gain for margin expectations, but does not quantify it; traders should verify whether underlying margin expansion is broad-based.

Relevance 8/10Novelty 7/10Timing: ahead of Q3 print, with updated FY26 revenue guidance

Background

ABB reported Q2 results with strong revenue and orders growth and referenced value creation from its Rotork acquisition.

Company-level read

Ticker impact

$ABBNYBullishMedium confidence
Context

ABB reported Q2 net income of $1.23B, EPS $0.68, revenues up 14%, and raised its FY26 revenue outlook.

Expected impact

Moderately positive bias for ABB shares into the next earnings cycle as investors price in stronger 2026 growth and improving margins.

Evidence & confidence

The article provides multiple fresh datapoints: Q2 profit/revenue/order growth, Q3 comparable revenue growth expectation, and an upgraded FY26 revenue view with book-to-bill positivity.

Market effects

Supports sentiment for industrial electrification and automation demand, potentially improving read-through for peers with similar end-markets.

Primarily global industrials sentiment; no specific regional catalyst beyond ABB’s outlook.

Signals continued capex/electrification spending resilience, relevant to multinational industrial supply chains.

Counterpoint

Orders growth and margin improvement may partially reflect timing and one-off items; investors may discount guidance if backlog conversion or execution slips.

Key entities

  • ABB Ltd

    Swiss industrial electrification and automation company reporting Q2 results and lifting FY26 revenue guidance.

  • Rotork

    ABB acquisition referenced as expanding its automation portfolio.

Related articles

$HYMed

Hyster-Yale’s (HY) Bookings Boom Meets A Widening Loss

Hyster-Yale (HY) reported Q2 results with bookings up 106% YoY to $680M, but a net loss of $31.6M. Revenue rose 2% QoQ to $812.9M, and operating cash flow turned positive at $17M. Management expects full-year bookings to exceed 2025, but warns of slow margin recovery due to competitive pricing and tariffs.

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

$CRMDMedAI 8/10

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.